November 15, 2012 - Supplement   (View All Issues)

    CE Activity Instructions

    *Corresponding author, MediCom Worldwide, Inc, 101 Washington Street, Morrisville, PA 19067,

    Activity Release Date: November 15, 2012
    Period of Validity:
    November 15, 2013

    Program Overview

    This activity presents highlights from a satellite symposium held in...


    This supplement to The ASCO Post highlights the proceedings of a satellite symposium that was presented as a case-based roundtable discussion titled, Monitoring, Treatment Resistance, and Treatment Failure in Chronic Myeloid Leukemia: Breaking Barriers to Improved Outcomes and Looking Forward to a...

    Treatment Goals, Molecular Monitoring, and the Role and Use of Guideline Recommendations

    The importance of achieving a certain level of response with imatinib (Gleevec) by 3 months in patients with chronic myeloid leukemia (CML) had previously been established in the IRIS (International Randomized Study of Interferon and STI571) trial.1 Analysis of data from this trial showed that...

    Beyond Molecular Monitoring: Cytogenetic Testing and Mutational Analysis in Chronic Myeloid Leukemia

    Cytogenetic analysis remains an important component of patient monitoring until a complete cytogenetic response is achieved. In addition, the ability of conventional cytogenetics to identify additional chromosomal abnormalities not detected by fluorescence in situ hybridization is noteworthy. Jorge ...

    Defining and Recognizing the Causes of Imatinib Resistance and the Importance of Adherence

    Imatinib (Gleevec) is a highly effective therapy for the majority of patients with chronic myeloid leukemia (CML). In the IRIS study, only 30% of patients could be considered to have failed imatinib treatment after 6 years.1 However, these 30% of patients are a substantial minority. John Goldman,...

    Managing Treatment Failure in Chronic Myeloid Leukemia

    As John Goldman, DM, FRCP, FRCPath, FMedSci, discussed earlier, a substantial minority of patients with chronic myeloid leukemia (CML) experience treatment failure. Jorge Cortes, MD, of The University of Texas MD Anderson Cancer Center, introduced this session with two patient cases to illustrate...

    Defining a Cure for Chronic Myeloid Leukemia and Strategies to Achieve this Goal

    In chronic myeloid leukemia (CML), continued long-term therapy that prevents both progression to accelerated-phase disease and the emergence of resistance may be thought of as an “operational” or “functional” cure. However, long-term disease control without the requirement for continuous treatment...



click me